Table 1.

Pre-and Post-Treatment Plasma Levels of SAMe and other One-Carbon-Cycle Intermediates

	Pre-Treatment					Post-Treatment					Changes in treatment arms
	SAMe (n=20)		Placebo (n=15)		Significance* (SAMe vs PBO)	SAMe (n=20)		Placebo (n=15)		Signif** (SAMe vs PBO)	Signif+ (SAMe arm)	Signif++ (PBO arm)
	Mean	SD	Mean	SD		Mean	SD	Mean	SD
SAMe (nmol/L)	82.9	22.44	71.24	12.44	t=1.81, p=0.08	503.77	535.76	81.27	31.52	p=0.0035	t=-3.5, p=0.002	t=-1.1, p=0.29
SAH (nmol/L)	35.7	6.74	30.87	10.56	t=1.65, p=0.11	56.1	18.25	30.14	8.25	p<0.0001	t=-4.9, p<0.0001	t=0.2, p=0.81
tHCY (umol/L)	9.78	2.27	8.04	2.31	t=2.22, p=0.03	10.57	3.64	7.97	1.9	p=0.0016	t=-1.4, p=0.19	t=0.18, p=0.86
MET (umol/L)	13.28	10.07	11.13	7.65	t=0.69, p=0.49	12.34	6.35	11.07	5.73	p=0.51	t=0.43, p=0.68	t=0.04, p=0.97
5-MTHF (nmol/L)	34.59	18.19	26.53	10.06	t=1.54, p=0.13	50.68	83.04	30.28	13.79	p=0.19	t=-1.0, p=0.32	t=-0.92, p=0.37

^*Based on two-sample t-test for SAMe versus Placebo.

^**Based on Fisher’s Protected Least Significant Difference (PLSD after adjusting for pre-treatment levels) for SAMe versus Placebo.

⁺Paired t-test for pre and post treatment levels of intermediates for SAMe arm.

⁺⁺Paired t-test for pre and post treatment levels of intermediates for Placebo arm.